# A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct07622186/  
OnCo record `nct07622186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib, Furmonertinib, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07622186 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 150 participants planned, started 2026-07-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB571 for injection, Osimertinib, Furmonertinib, carboplatin, Cisplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07622186
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07622186: https://clinicaltrials.gov/study/NCT07622186

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07622186.json